Allarity Therapeutics, Inc.
corporate_fare Company Profile
Allarity Therapeutics, Inc. (NASDAQ:ALLR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for ALLR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for ALLR spans 8-K, 10-Q, DEFA14A, 424B3.
Recent high-impact activity:
- Allarity Swaps $3M of Streeterville Debt for Senior Preferred, Gives Lender 33% of ATM Proceeds
- Allarity Posts $6.2M Q3 Loss as Going-Concern Doubt Deepens
- Allarity Q3 10-Q Flags Going-Concern Doubt and Nasdaq Equity Deficiency
- Allarity Settles $4.9M Novartis Liability for $1M; Books First CLIA Lab Contract
- Allarity Terminates $6.0M Tumim Equity Line, Seeks Alternative Financing
Financial Snapshot
Short Interest & Short Volume
1.85 days to coverFINRA reported short interest of 230,750 shares in ALLR as of the October 30, 2026 settlement, a 37.3% increase from the prior period — about 1.9 days to cover at its recent average daily volume. On November 20, 2026, 25.1% of ALLR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.